Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)

Lung Cancer

Volumn 32, Issue 1, 2001, Pages 61-69

  Shibayama, Takuo ^a,b   Ueoka, Hiroshi ^b   Nishii, Kenji ^a,b   Kiura, Katsuyuki ^b   Tabata, Masahiro ^b   Miyatake, Kazuyo ^b   Kitajima, Takuji ^a,b   Harada, Mine ^b  

^a Anti Tuberculosis Association   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Diagnosis; Neuron specific enolase (NSE); Pro gastrin releasing peptide (ProGRP); Prognostic factor; Small cell lung cancer

Indexed keywords

GASTRIN RELEASING PEPTIDE; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; PROTEIN PRECURSOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SERUM; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0035103446     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00205-1     Document Type: Article

References (19)

1. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
2. Final results of a phase III study of concurrent versus sequential radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) study
3. Serum neuron-specific enolase: a marker for disease extent and response to therapy for small-cell lung cancer
4. Serum neuron specific enolase (NSE) levels in patients with non-small-cell lung cancer
5. A gastrin-releasing peptide from the porcine non-antral gastric tissue
6. Peptide hormone production in primary lung tumors
7. Peptide hormone production in small cell lung carcinomas with particular reference to gastrin-releasing peptide
8. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma
9. Pro-gastrin-releasing peptide(31-98) is a specific tumor markar in patients with small cell lung carcinoma
10. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor markar for small-cell lung carcinoma: Development and evaluation
11. Basic principles of ROC analysis
12. The meaning and use of the area under a reciever operating characteristics (ROC) curve
13. A method of comparing the areas under receiver operating characteristics curves derived from the same cases
14. Nonparametric estimation for incomplete observations
15. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
16. Regression models and life tables
17. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement
18. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer
19. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer